

Author's Accepted Manuscript

Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial

Benjamin T. Ristau , Judi Manola , Naomi B. Haas , Daniel Y.C. Heng , Edward M. Messing , Christopher G. Wood , Christopher J. Kane , Robert S. DiPaola , Robert G. Uzzo



PII: S0022-5347(17)77148-0
DOI: [10.1016/j.juro.2017.07.042](https://doi.org/10.1016/j.juro.2017.07.042)
Reference: JURO 14866

To appear in: *The Journal of Urology*
Accepted Date: 10 July 2017

Please cite this article as: Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG, Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial, *The Journal of Urology*® (2017), doi: 10.1016/j.juro.2017.07.042.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial

Benjamin T. Ristau^a, Judi Manola^b, Naomi B. Haas^c, Daniel Y. C. Heng^d, Edward M. Messing^e, Christopher G. Wood^f, Christopher J. Kane^g, Robert S. DiPaola^h, and Robert G. Uzzo^a

^aFox Chase Cancer Center, Temple Health, Philadelphia, PA, USA

^bDana-Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Boston, MA, USA

^cAbramson Cancer Center of The University of Pennsylvania, Philadelphia, PA, USA

^dTom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada

^eDepartment of Urology, University of Rochester, Rochester, NY, USA

^fThe University of Texas MD Anderson Cancer Center, Houston, TX, USA

^gMoore's Cancer Center, University of California, San Diego, La Jolla, CA, USA

^hUniversity of Kentucky College of Medicine, Lexington, KY, USA (current location); Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA (former location)

Corresponding Author:

Benjamin T. Ristau, MD

Fox Chase Cancer Center, Temple Health

Division of Urologic Oncology

333 Cottman Avenue

Philadelphia, PA 19111

Phone: 215-728-3096

Fax: 215-214-4035

benristaumd@gmail.com

Keywords: adjuvant therapy; clinical trials; lymphadenectomy; overall survival; renal cell carcinoma

Word Count (Abstract): 248

Word Count (Manuscript): 2,495

This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820, CA180794, CA180821, CA180858, CA180863, CA180888, and Canadian Cancer Research Institute #021039 and #704970. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

Download English Version:

<https://daneshyari.com/en/article/8771780>

Download Persian Version:

<https://daneshyari.com/article/8771780>

[Daneshyari.com](https://daneshyari.com)